Fibank and Bitpanda Forge Strategic Partnership to Launch Integrated Crypto Asset Access via My Fibank Mobile App

SOFIA, Bulgaria, Oct. 12, 2026 /PRNewswire/ -- Fibank (First Investment Bank) and Bitpanda GmbH have entered into a strategic partnership agreement. This landmark collaboration will grant Fibank customers direct technical access to premium crypto asset services provided by Bitpanda GmbH – an Austria-based, fully licensed crypto asset service provider – directly through the My Fibank mobile application.

Through this pioneering alliance, Fibank becomes the first bank in Bulgaria to offer its customers seamlessly integrated access to crypto asset trading. As digital products, these assets differ from traditional deposits and financial instruments, carrying no guarantees or compensation schemes. Consequently, customers are encouraged to thoroughly familiarize themselves with their unique characteristics and inherent risks.

Once approved after a straightforward application process, Fibank customers will be able to access a comprehensive suite of crypto asset services 24/7 via Bitpanda's integrated interface inside My Fibank, with a minimum investment threshold of just €1. This state-of-the-art technical integration empowers bank customers to track, manage, and optimize their digital assets alongside their traditional financial portfolio, all within a single application.

"Customer financial habits are evolving rapidly, and it is vital for My Fibank to innovate alongside them. The partnership with Bitpanda is a natural next step in the development of the application as a digital platform through which customers can conveniently use an ever-wider range of financial solutions. For us, it is particularly important that this new opportunity is being realized alongside an established European technology partner and in compliance with applicable regulatory requirements," commented Nikola Bakalov, CEO of Fibank.

Crypto asset services will be provided by Bitpanda. Access to the services will depend on the acceptance of the potential customer by Bitpanda and on the company's applicable terms and criteria. The integration of Bitpanda's infrastructure complements the features available through My Fibank and marks the next step toward turning My Fibank into a comprehensive digital financial environment, providing unified and mobile access to banking, savings, and investment solutions.

"Digital assets are becoming part of mainstream finance, and banks are playing a central role in that shift. At Bitpanda Enterprise, we provide the infrastructure and technology for that. Together with Fibank, we are putting that into practice in Bulgaria, bringing crypto to more than one million customers through a banking experience they already know and trust." stated Nadeem Ladki, Global Head of Bitpanda Enterprise.

The partnership between Fibank and Bitpanda comes at a time when an increasing number of European banks are seeking sustainable, regulatory-compliant solutions to meet the growing demand for digital asset trading. In Bulgaria and the wider region, such offerings remain limited, positioning Fibank as the first bank in Bulgaria and among the vanguard of EU credit institutions to provide direct access through its digital channels to Bitpanda's user interface, enabling customers to utilize Bitpanda's crypto asset services.

About Fibank

Fibank (First Investment Bank) is one of the leading banking institutions in Bulgaria and the largest bank with Bulgarian-owned capital. It has evolved into a modern financial group with its core operations in the Republic of Bulgaria and a regional footprint through a branch in Cyprus and a subsidiary bank in Albania. The Bank holds solid market positions and ranks among the key players in the Bulgarian banking sector in terms of assets, customer base, and the breadth of financial solutions it offers.

Fibank has established itself as an innovative, technology-driven and customer-focused financial institution, offering a broad range of products and services to retail clients, small and medium-sized enterprises, and large corporate customers. With strong expertise in corporate banking, trade finance, international payments and card services, the Bank is among the preferred financial partners of Bulgarian businesses. It combines deep knowledge of the local market, flexibility in structuring financial solutions, and the capacity to support both the day-to-day banking needs of companies and more complex transactions related to investment financing, working capital, guarantees, letters of credit and cross-border payments.

In recent years, Fibank has consistently strengthened its position as an innovator in the banking sector through the development of modern digital channels, online and mobile banking, remote services, intelligent customer-service solutions, and a new generation of card and payment products. The Bank is also among the pioneers in Bulgaria in offering specialized products related to investment gold, precious metals, savings and investment solutions, as well as in introducing new technological models for faster, more convenient and more secure banking.

About Bitpanda Enterprise

Bitpanda Enterprise is the institutional infrastructure arm of Bitpanda, providing a unified technology that enables banks, fintechs, brokers, trading firms, family offices and corporate clients to access digital asset capabilities at scale. It brings together investment infrastructure, liquidity, custody, payments, stablecoins and tokenisation within one integrated ecosystem. Designed for long-term institutional growth, Bitpanda Enterprise prioritises transparency and scalability, helping institutions bridge traditional finance with the digital economy. Through its institutional partnerships, Bitpanda Enterprise currently provides digital asset access to end users across the EU, the UK, the UAE and Latin America. Its partners include N26, Société Générale, Deutsche Börse Group, selected Raiffeisen Banks, RAKBANK and Onda Finance, among others.

Share this article

From Bank Back Offices to Power Grids, Frontier AI Labs Push Deeper Into the Enterprise

VANCOUVER, BC, Oct. 12, 2026 /PRNewswire/ -- Canada News Group News Commentary - The two best-known private AI developers each made a series of announcements over the past two weeks, and most of them pointed in the same direction: selling to large organizations. Anthropic released a new low-cost model, launched a cybersecurity program with eleven founding partners and committed $250 million across two new initiatives, while OpenAI brought its newest models to every ChatGPT user and expanded its work with enterprise software and advertising partners. Neither company is publicly traded, but several listed companies are now named partners in that work. Active Companies from around the markets with current developments this week include: Atlassian Corporation (NASDAQ: TEAM), Palo Alto Networks, Inc. (NASDAQ: PANW), Booz Allen Hamilton Holding Corporation (NYSE: BAH), Accenture plc (NYSE: ACN), Barclays PLC (NYSE: BCS).

Anthropic introduced Claude Haiku 5.5 on October 7, calling it "the cheapest, fastest, and most capable small model we've ever released." The company said the model costs around 75% less to run on average than Haiku 4.5 and is available on Amazon Web Services, Google Cloud and Microsoft Azure. A day later it committed $150 million over three years to the U.S. government's Genesis Mission, which uses AI to accelerate scientific research across more than 15 federal agencies, including NASA, the National Institutes of Health and the National Science Foundation. On October 2 it launched Claude Frontier Academy, a $100 million program to train 10,000 engineers inside customer and partner organizations by the end of 2027.

OpenAI began rolling out GPT-6 and a new interactive interface it calls Intelligent UI to all ChatGPT users on October 7, citing "more than 1.2 billion people who use ChatGPT each week." On October 5 it announced a new visual ad format in ChatGPT, with testing in the U.S. later this month for an initial group of advertisers. The company's finances also drew attention: on October 8, the Financial Times reported that OpenAI told investors its annualized revenue was nearing $50 billion at the end of September, a figure below the roughly $70 billion that had circulated in earlier media reports.

For investors, the most direct exposure to this activity runs through the listed companies that build on, distribute or deploy these models, and several of them were named in the labs' announcements this month.

CONTINUED... Read more on the companies driving the AI trade in The Roadmap at: stockpreachers.com

In other industry developments and happenings in the market this week include:

Atlassian Corporation (NASDAQ: TEAM)

Atlassian and OpenAI expanded their partnership on October 6. Under the new agreement, OpenAI frontier models will power agents across Atlassian's platform and its Rovo AI product, and Atlassian receives expanded access to OpenAI's latest models. More than 3,000 Atlassian developers use OpenAI's Codex, and OpenAI will continue to use Jira to manage critical company workflows.

"Uniting OpenAI frontier capabilities with Atlassian's Teamwork Graph brings deep organizational context to enterprise work," said Jamil Valliani, Head of Product, AI at Atlassian.

Palo Alto Networks, Inc. (NASDAQ: PANW)

Palo Alto Networks is one of eleven founding partners in Anthropic's new Critical Infrastructure Defense Program, part of the Anthropic Cyber Mission announced on October 8. The program gives trusted security providers access to frontier Claude models, on-site engineers and threat research to help protect operational technology such as power grids, water systems and transportation networks, along with government systems.

"Threat actors are using AI to find and exploit exposures at machine speed," said Sam Rubin, Senior Vice President, Unit 42, Palo Alto Networks.

Booz Allen Hamilton Holding Corporation (NYSE: BAH)

Booz Allen is also a founding partner in the Critical Infrastructure Defense Program, alongside companies including CrowdStrike, Deloitte, Dragos, Hitachi, Nozomi Networks, PwC and Rockwell Automation. Anthropic said it has offered Claude models and technical support to more than half of U.S. states and some large public critical infrastructure operators since launching its state and local cyber defense program in June.

"Operational technology is the next frontier for autonomous AI-enabled attacks," said Andrew Turner, President of Commercial Cyber, Booz Allen.

Accenture plc (NYSE: ACN)

Accenture appears in both of Anthropic's new programs. It is a launch partner in Claude Frontier Academy, whose first offering combines an in-person program with a 12-week residency in which engineers lead a real Claude project at their own organization, and it is a founding partner in the Critical Infrastructure Defense Program. Other Academy launch partners include Bain, Capgemini, Deloitte, McKinsey, Morgan Stanley and Novo Nordisk.

"Anthropic built the residency the same way we think about the role," said Ram Ramalingam, FDE and Software & Platform Engineering lead at Accenture.

Barclays PLC (NYSE: BCS)

Barclays is extending Claude across its global operations, Anthropic said on October 1. The bank expects Claude Code adoption to reach 50% of its developers by the end of 2026, and its Claude-powered Colleague Knowledge Assistant has more than 16,000 users supporting staff who serve over 20 million U.K. retail customers. In Global Markets, Claude models classify, enrich and route about 120,000 client emails per day.

"We're moving towards AI as an increasingly agentic capability," said Craig Bright, Group Co-Chief Operating Officer, Barclays.

Know Which AI Names Are Moving Before Monday's Open

The Roadmap from Stock Preachers is an in-depth market report published every Monday, Wednesday and Friday, covering the stocks, sectors and themes driving the market, including the companies building and deploying AI. Access is free during the public beta at stockpreachers.com.

Contact Information:

canadanewsgroup.com  

Media Contact: [email protected] 

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. It is neither an offer nor a recommendation to buy or sell any security.

This article is being distributed by Canada News Group, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution, and MEL has no advertising or digital media agreement with any company mentioned in this article. The companies mentioned have not reviewed or approved this article.

Market Equities and its owners, operators, directors, and affiliates may, from time to time, hold positions in securities mentioned in this article or in the broad-market index funds that track them, and reserve the right to buy, sell, or hold such securities at any time without further notice.

Information in this article was obtained from sources believed to be reliable, including company announcements and public reporting, but its accuracy cannot be guaranteed. Investing in securities involves risk, including the possible loss of some or all of your investment.

References to the companies named in this article are provided solely as market and sector context and as summaries of public company announcements. Anthropic and OpenAI are privately held and their securities are not publicly traded. No partnership, affiliation, or endorsement is implied between the publisher and any company mentioned, and nothing in this article is a recommendation to buy, sell, or hold any security. Quotations attributed to executives are reproduced from the announcements in which they appeared. Revenue figures attributed to press reports have not been confirmed by the company concerned. Model performance and cost figures are as stated by the developer.

Stock Preachers Disclosure. Stock Preachers, including its market report The Roadmap, is a market-commentary publication owned by MEL, and references to it in this article constitute promotion of an affiliated product. Stock Preachers is not a broker-dealer, and nothing on its website, in The Roadmap or in this article is financial, investment, tax, or legal advice. Its content is for informational and educational purposes only. Always do your own research before making any investment decision.

Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially. Readers should review each company's filings with the SEC.

SOURCE Canada News Group

Share this article

HCLTech to establish a dedicated Anthropic Business Unit and Center of Excellence (CoE) to accelerate deployments of Claude in enterprise environments

HCLSoftware becomes an Anthropic ISV partner, embedding Claude and Claude Code into select enterprise products with frontier safety guardrails

SANTA CLARA, Calif. and NOIDA, India, Oct. 12, 2026 /PRNewswire/ -- HCLTech (NSE: HCLTECH) (BSE: HCLTECH), a leading global technology company, today announced a Global Premier Partnership with Anthropic, to accelerate enterprise adoption of Agentic AI with a focus on safety, cybersecurity and governance. HCLTech's services teams will build industry solutions and offerings powered by Claude, Cowork and Claude Code, while HCLSoftware, as an Anthropic ISV partner, will embed these into its select enterprise products.

HCLTech will establish a dedicated Anthropic Business Unit with a Center of Excellence (CoE) to build Agentic AI solutions and provide secure sandbox environments for enterprise deployments of Claude through FDEs. It will also help clients adopt AI-native engineering practices, train their workforces and build the organizational capabilities needed to operate Agentic AI safely at scale.

As an ISV, HCLSoftware will embed Claude capabilities and have access to advanced models to integrate into select enterprise products across cybersecurity, automation and business process application and application development, including HCL BigFix and HCL AppScan, while enabling Actian AI analyst.

Additionally, HCLTech will integrate Claude and Claude Code in its agentic software engineering platform AI Force across IT support, code remediation and digital employee services. These workflows are supported by policy guardrails, exception handling and human oversight for high-impact changes.

"AI can only be as useful as it is trustworthy, and we build Claude to give companies the confidence to bring it into their most sensitive and valuable work. HCLTech manages those kinds of systems for banks, hospitals, telecom companies and manufacturers, and we're excited to partner with them as they integrate Claude and Claude Code. This partnership — and our broader commitment to advancing capability and safety together — is how AI will change the way entire industries run for the better," said Daniela Amodei, Co-founder and President of Anthropic.

"Few technology companies combine the scale of a global systems integrator with the product depth of an ISV. That gives us a rare advantage to securely engineer and deploy Agentic AI at scale and deliver the business outcomes that matter most to our clients. Our partnership with Anthropic further strengthens our capabilities to achieve the same," said C Vijayakumar, CEO & Managing Director, HCLTech.

The collaboration builds on HCLTech's broader AI capabilities across engineering, data, cloud and software. By combining these capabilities with Anthropic's commitment to advancing AI and safety together, HCLTech will help clients move from AI experimentation to enterprise deployment safely and at scale.

About HCLTech

HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around AI, digital, engineering, cloud and software, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology & Services, Semiconductor, Telecom and Media, Retail and CPG, Mobility and Public Services. Consolidated revenues as of 12 months ending June 2026 totaled $14.8 billion. To learn how we can supercharge progress for you, visit hcltech.com.

For further details, please contact:

Meredith Bucaro, Americas - [email protected]

Elka Ghudial, Europe - [email protected]

James Galvin, APAC - [email protected]

Nitin Shukla, India, Middle East & Africa- [email protected]

SOURCE HCLTech

Share this article

Key Takeaways

- Cablenet has selected Harmonic's cOS™ virtualized broadband platform to modernize its DOCSIS access network.

- The distributed access architecture (DAA) deployment supports Cablenet's delivery of high-performance gigabit speeds and future speed tiers over its access networks.

- The cOS platform simplifies operations, enhances subscriber QoE and lowers OPEX.

SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that Cablenet Communication Systems plc ("Cablenet"), the second largest fixed network operator in Cyprus and a leading converged fixed and mobile operator, is modernizing its broadband access network with Harmonic's market-leading cOS™ virtualized broadband platform. The deployment strengthens Cablenet's gigabit service capability, simplifies network operations and enhances subscribers' quality of experience (QoE).

"The real measure of network modernization is the difference it makes for our customers," said Panayiotis Kouloumbrides, Chief Core Networks Officer at Cablenet. "Harmonic's cOS platform strengthens our DOCSIS 3.1+ network footprint, giving our customers fast, consistent gigabit broadband they can count on today, tomorrow and always, with a clear path to even higher speeds. We believe that broadband should simply work for our customers, every time."

A Platform Built for the Next Generation of Broadband

With Harmonic's virtualized cOS platform in a DAA with low-power Oyster nodes, Cablenet can introduce significantly higher speeds across its footprint and efficiently scale services as subscriber needs evolve. The cOS software-based platform also preserves flexibility for Cablenet's longer-term multi-technology network strategy.

Consolidating Infrastructure and Reducing OPEX

The cOS platform supports Cablenet's approach to consolidating data centers and simplifying hub-site infrastructure as part of the operator's cost-optimization initiative. By moving network functions from legacy hardware to Harmonic's software-based platform, the operator can reduce space, power and wiring requirements and lower OPEX while streamlining operations.

Gaining Access to Operational Intelligence

With the transition to the cOS platform, Cablenet can now access Harmonic's Central AI-driven network intelligence for greater network visibility, more efficient monitoring, faster troubleshooting and improved service assurance.

"Operators need a practical path to enhance services today while preserving the flexibility to evolve their networks for tomorrow," said Stefan Meier, Vice President of Sales, Europe, at Harmonic. "Our cOS platform provides Cablenet with a strong foundation to modernize its network, simplify operations and deliver a superior broadband experience. We're pleased to support Cablenet's forward-looking network strategy and its commitment to delivering faster, more consistent connectivity and a better quality of experience for its subscribers."

Harmonic will showcase its latest broadband innovations at Network X, Oct. 13-15 in booth L71. To set up a meeting with Harmonic, visit www.harmonicinc.com/events/network-x.

Harmonic is the market share leader in cable broadband equipment, virtual CMTS and DAA, according to Dell'Oro Group, the trusted source for market information about the telecommunications, networks and data center IT industries. The company's market-leading cOS platform powers next-gen broadband services through more than 48 million CPE devices worldwide for leading operators in North America, Europe, Latin America and Asia. To learn more about Harmonic solutions, visit www.harmonicinc.com.

About Harmonic

Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband solutions, is transforming multi-gigabit connectivity. The company's industry-leading cOS™ virtualized broadband platform, suite of solutions for fiber and DOCSIS, and a growing portfolio of AI-powered network intelligence solutions, enable broadband service providers to simplify operations, deliver exceptional subscriber experiences and expand revenue streams. With thousands of vCMTS servers and hundreds of thousands of RPDs deployed globally, Harmonic powers next-generation broadband services with five-nines reliability. Anchored with a customer-first approach and driven by a legacy of innovation, Harmonic supports broadband service providers at every stage of their network evolution. More information is available at www.harmonicinc.com. 

Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning Harmonic's business and the anticipated capabilities, advantages, reliability, efficiency, market acceptance, market growth, specifications and benefits of Harmonic products, services and technology are forward-looking statements. These statements are based on our current expectations and beliefs and are subject to risks and uncertainties, including the risks and uncertainties more fully described in Harmonic's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2025, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. The forward-looking statements in this press release are based on information available to Harmonic as of the date hereof, and Harmonic disclaims any obligation to update any forward-looking statements.

About Cablenet

Cablenet Communication Systems plc is the second largest fixed network operator in Cyprus and a converged provider of broadband, TV, fixed telephony and mobile services to residential, business, wholesale and government customers. Cablenet runs an island-wide HFC/DOCSIS and FTTH network, mobile network, and IP/MPLS and DWDM transport backbone. Cablenet has become the island's fastest-growing converged operator, and it continues to invest in next-generation fixed and mobile infrastructure. Cablenet is a subsidiary of GO plc, Malta's leading telecommunications group, which is listed on the Malta Stock Exchange. More information is available at www.cablenet.com.cy.

SOURCE Harmonic Inc.

Share this article

- Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026

ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.

Along with a clinical program overview, the event will feature perspectives from REGENXBIO management and leading retina specialists on the treatment landscape, unmet need, ATMOSPHERE® and ASCENT® pivotal trials, and commercial readiness of sura-vec in wet AMD.

Featured key opinion leaders include:

- Gaurav Shah, M.D., FASRS, California Pacific Medical Center, Sutter Health

- Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates

- Lejla Vajzovic, M.D., FASRS, Duke University School of Medicine

- Rahul Khurana, M.D., FASRS, Northern California Retina Vitreous Associates, University of California at San Francisco

- Ramanath Bhandari, M.D., FASRS, Springfield Clinic Eye Institute

Sura-vec in Wet AMD: Clinical Program Overview and Expert Perspectives

Date: Tuesday, October 20, 2026

Time: 1:00 p.m. ET – 4:00 p.m. ET

Location: New York, NY and Virtual

Registration for the webcast is available at this LINK.   

An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the event.

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack

Corporate Communications

[email protected] 

Investors:

George E. MacDougall

Investor Relations

[email protected] 

SOURCE REGENXBIO Inc.

Share this article

DUBLIN, Oct. 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ® (terlipressin) will be shared at the American College of Gastroenterology Annual Meeting, taking place October 9-14, 2026.

"We are pleased to share these findings with the medical community because they contribute to our understanding of this challenging and rapidly progressive condition," said Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center and presenting author. "The exploratory analysis expands the clinical evidence on the use of terlipressin in liver transplant–ineligible patients and can help providers support those affected by HRS-AKI."

TERLIVAZ is the first and only FDA‑approved therapy indicated to improve kidney function in adults with HRS‑AKI.

Presentation Details

- Date: October 12

- Title: Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial

- Authors: Nancy Reau, MD; Kavish Patidar, DO; Laurie Larson, MSN, APRN; HoChong Gilles, DNP, APRN; R. Todd Frederick, MD; Kevin Regner, MD, MS; Anooj Shah, PharmD, MBA; Richard Wu, PhD; Christopher White, MD, MSPH; Nneka N. Ufere, MD, MSCE

About Hepatorenal Syndrome-Acute Kidney Injury

Hepatorenal syndrome–acute kidney injury (HRS-AKI) is a life-threatening condition in adults with advanced liver disease that is marked by a rapid decline in kidney function1 and is associated with high morbidity and mortality.2 It is an acute medical emergency that requires hospitalization.3 A U.S. study based on national data revealed that the estimated annual number of inpatients diagnosed with HRS between 2018 and 2023 increased from 42,930 to 63,381.4

INDICATION

TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

LIMITATION OF USE

- Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE

- TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO2) before initiating TERLIVAZ. 

- Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO2 90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO2 decreases below 90%.

Contraindications

TERLIVAZ is contraindicated:

- In patients experiencing hypoxia or worsening respiratory symptoms.

- In patients with ongoing coronary, peripheral, or mesenteric ischemia.

Warnings and Precautions

- Serious or Fatal Respiratory Failure: Obtain baseline oxygen saturation and do not initiate TERLIVAZ in hypoxic patients. Monitor patients for changes in respiratory status using continuous pulse oximetry and regular clinical assessments. Discontinue TERLIVAZ in patients experiencing hypoxia or increased respiratory symptoms.

Manage intravascular volume overload by reducing or discontinuing the administration of albumin and/or other fluids and through judicious use of diuretics. Temporarily interrupt, reduce, or discontinue TERLIVAZ treatment until patient volume status improves. Avoid use in patients with ACLF Grade 3 because they are at significant risk for respiratory failure.

- Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed. For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.

- Ischemic Events: TERLIVAZ may cause cardiac, cerebrovascular, peripheral, or mesenteric ischemia. Avoid use of TERLIVAZ in patients with a history of severe cardiovascular conditions or cerebrovascular or ischemic disease. Discontinue TERLIVAZ in patients who experience signs or symptoms suggestive of ischemic adverse reactions.

- Embryo-Fetal Toxicity: TERLIVAZ may cause fetal harm when administered to a pregnant woman. If TERLIVAZ is used during pregnancy, the patient should be informed of the potential risk to the fetus.

Adverse Reactions

- The most common adverse reactions (≥10%) include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea.

Please click here to see full Prescribing Information, including BOXED WARNING.

About Keenova

Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit www.keenova.com.

Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations, and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Information Regarding Forward-Looking Statements

This release contains forward-looking statements, including with regard to TERLIVAZ®, the efficacy, safety, potential treatments or indications, therapeutic outcomes or treatment responses of this product, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with TERLIVAZ; and other risks identified and described in more detail in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Keenova's most recent Annual Report on Form 10-K, and other filings and furnishings with the Securities and Exchange Commission (SEC), all of which are available on the SEC's website (www.SEC.gov) and Keenova's website (www.keenova.com). The forward-looking statements made herein speak only as of the date hereof and Keenova does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

References

- Wong RJ, Balasubramanian J, Panaccio M, Huang X. Acute kidney injury and hepatorenal syndrome among hospitalized patients with chronic liver disease. JAMA Netw Open. 2025;8(5):e2511816.

- Loftus M, Brown RS Jr, El-Farra NS, Owen EJ, Reau N, Wadei HM, Bernstein D. Improving the management of hepatorenal syndrome–acute kidney injury using an updated guidance and a new treatment paradigm. Gastroenterol Hepatol (N Y). 2023;19(9):527-536.

- National Organization for Rare Disorders. Hepatorenal syndrome. Available at https://rarediseases.org/rare-diseases/hepatorenal-syndrome. Accessed March 17, 2026.

- Goyes M, et al. Increasing incidence, cost, and mortality of AKI and HRS in hospitalized patients with cirrhosis. JAMA Netw Open. 2025;8(5):e2511822.

SOURCE Keenova Therapeutics

Share this article

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026, in Nashville, Tennessee.

The study, "Development and Implementation of a Cirrhosis Clinical Pathway: Outcomes of a 6-Month Pilot Study," assessed the feasibility and impact of a multidisciplinary clinical pathway designed to reduce variability in cirrhosis care and improve adherence to guideline-recommended management practices.

Cirrhosis is associated with significant morbidity and healthcare utilization, yet management approaches often vary across clinical settings. To address this challenge, investigators developed a standardized pathway informed by current clinical guidelines and evidence-based practices, with contributions from both academic and community-based healthcare providers.

The pathway was implemented across five community gastroenterology practices as part of a six-month quality improvement initiative. Using population health analytics, investigators monitored adherence to five key performance indicators, including follow-up office visit, laboratory testing, nonselective beta-blocker use in patients with varices, hepatic encephalopathy treatment, and enrollment in chronic care management programs.

The analysis included 4,251 patients with cirrhosis and demonstrated measurable improvements across several care metrics during the six-month pilot period:

- Office visit adherence increased from 46.9% at baseline to 51.1%, representing a 9.0% relative improvement.

- Recommended laboratory monitoring adherence increased from 61.5% to 63.5%, a 3.2% relative improvement.

- Non-selective beta-blocker treatment rates among patients with varices increased from 47.2% to 48.8%, a 3.4% relative improvement.

- Medication treatment rates for reducing hepatic encephalopathy recurrence increased from 60.2% to 64.9%, a 7.8% relative improvement.

- Enrollment in chronic care management/principal care management programs increased from 11.7% to 12.8%, representing a 9.4% relative improvement.

The investigators concluded that implementation of a standardized cirrhosis clinical pathway, supported by population health analytics, was feasible in community practice and resulted in improved adherence to guideline-based monitoring and treatment recommendations.

"These results highlight the value of a clinical pathway in helping providers deliver more consistent, guideline-based care for patients with cirrhosis," said Peng-Sheng (Brian) Ting, MD, principal investigator of the pilot initiative. "As the burden of liver disease continues to grow, broader adoption of proven care pathways may help close gaps in care, improve treatment adherence, and support better patient outcomes."

About the Study

The study leveraged the Cardinal Health PPS Analytics platform to identify gaps in care and monitor adherence to predefined clinical pathway benchmarks. Investigators believe the approach may serve as a scalable model for improving cirrhosis management in community practice settings and supporting delivery of guideline-concordant care.

The data presented in this release reflect findings submitted to and accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting & Postgraduate Course 2026. Findings should be considered preliminary until presented and further evaluated in peer-reviewed publications.

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

©2026 Salix Pharmaceuticals or its affiliates.

SOURCE Bausch Health Companies Inc.

Share this article

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management.

For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows. While advances in medical science have significantly improved diagnosis and treatment, the fundamental model has remained largely reactive.

Today, advances in AI, healthcare data and remote monitoring technologies are beginning to reshape this model. Wearable devices and remote patient monitoring ("RPM") technologies can support continuous collection of health indicators outside traditional clinical settings, while longitudinal and real-world healthcare data can provide a broader view of changes in an individual's health status. AI can help analyze these multidimensional datasets, identify potential risk signals and support more timely healthcare decisions.

Pomdoctor believes the convergence of these technologies is enabling healthcare to evolve from "diagnose and treat" toward "predict, alert and intervene," with particular relevance to chronic disease management, where continuous monitoring and timely intervention can play an important role in long-term health management.

Pomdoctor's Role in the Transition to Predictive Healthcare

Against this backdrop, Pomdoctor is positioning its healthcare ecosystem to participate in the transition toward predictive healthcare. The Company's strategy combines its existing healthcare operations and physician resources with AI, wearable technologies, RPM capabilities and real-world healthcare data.

Rather than developing these capabilities independently, Pomdoctor aims to integrate them into a coordinated healthcare management framework in which data generated through monitoring and healthcare interactions can support AI-driven analysis, physician follow-up and more personalized health management.

The Company believes its existing healthcare infrastructure and growing technology capabilities provide a foundation to support a more continuous, data-driven and proactive model of care.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented, "For generations, healthcare has largely focused on treating patients after illness or symptoms appear. New technologies are creating the opportunity to move healthcare intervention further upstream. We believe predictive healthcare will become an increasingly important part of future health management. By combining our healthcare operations, physician resources, real-world data and technology capabilities, we aim to help build the infrastructure needed to support this transition."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company's strategy to participate in the transition of healthcare from a reactive model toward a predictive and proactive model; the Company's plans to integrate AI, wearable technologies, remote patient monitoring ("RPM") capabilities and real-world healthcare data with its existing healthcare operations and physician resources into a coordinated healthcare management framework; the Company's pursuit of the development of a predictive healthcare data and services infrastructure; the Company's belief that its existing healthcare infrastructure and technology capabilities provide a foundation for a more continuous, data-driven and proactive model of care; expectations regarding the future role of predictive healthcare, including in chronic disease management; and the anticipated benefits of the Company's strategy for patients, healthcare providers and other ecosystem participants, including improved healthcare outcomes and long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "aims," "estimates," "projects," "intends," "plans," "pursues," "positions," "will," "would," "should," "could," "may" or other similar expressions. These forward-looking statements are based on the Company's current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties. Investors are urged to review the section entitled "Item 3. Key Information—D. Risk Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2026, and the Company's other filings with the SEC, which are available on the SEC's website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED

Investor Relations Department

Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: [email protected]

SOURCE POMDOCTOR LIMITED

Share this article

The 2026 Ivory Prize Summit to Spotlight Housing Solutions Communities Can Put to Work

National gathering at Arizona State University on Oct. 14 connects housing innovators, policymakers and developers to share knowledge and advance affordability

TEMPE, Ariz., Oct. 12, 2026 /PRNewswire/ -- As the housing affordability crisis continues to grip communities nationwide, Ivory Innovations is bringing the nation's top housing changemakers together to turn bold ideas into real-world action.

Ivory Innovations, an operating foundation and academic center based at the University of Utah, is hosting its annual Ivory Prize Summit on Oct. 14 at Arizona State University. The gathering aims to advance housing affordability by connecting promising innovations with the people and organizations positioned to put them into practice.

The summit fosters collaboration across sectors that too often address housing challenges separately. Its focus on systemic solutions will give attendees an opportunity to exchange ideas and build relationships across policy, development, research, and entrepreneurship.

"The most important thing that we can focus on as we seek to solve the broader issue of housing affordability is taking solutions that already exist and share them with the communities that need them the most." said Abby Ivory, co-founder and president of Ivory Innovations. "We're excited to be bringing industry experts and housing advocates together to share and discuss solutions to a problem that has such a huge impact on families across the country."

Featured presenters:

- Clark Ivory, Ivory Homes CEO and Ivory Innovations Co-founder

- Chris Herbert, Managing Director of Harvard's Joint Center for Housing Studies and Ivory Innovations Advisory Board Chairman

- Eric Kronberg, Principal at Kronberg Urbanists + Architects and Co-founder of Inc Codes

- Laurie Goodman, The Urban Institute's Housing Finance Policy Center Founder

- Jonathan Lawless, Bilt Rewards Head of Homeownership

- Dennis Steigerwalt, Housing Innovation Alliance President

- Alison Cook-Davis, Research Director at Arizona State University's Morrison Institute for Public Policy and Co-Director of the Arizona Research Center for Housing Equity and Sustainability

- Flavio Bravo, Arizona State Senator

- Shawnna Bolick, Arizona State Senator

- Nicole Newhouse, Director of the Arizona Housing Coalition

- Anakaren Lemus, Chief of Government Affairs for the Arizona Department of Housing

The summit will also honor the winners of the 2026 Ivory Prize for Housing Affordability, whose work illustrates how communities can approach affordability in three categories; Construction & Design, Finance, and Policy & Regulatory Reform. This year's winners are TradesFutures, the City of Boston's Boston Acquisition Fund, and the City of Chattanooga's Affordable Housing PILOT and the City of New Rochelle's Downtown Development initiative as co-winners.

These honorees created concrete starting points for a national conversation about housing solutions: preparing more people for construction careers, financing housing acquisition, and using local policy to support affordability and development.

The summit will also include presentations from the three teams that won Hack-A-House, an annual Ivory Innovations competition where college students nationwide propose innovative solutions to housing affordability. These presentations will be livestreamed, followed by a round of voting for the competition's Grand Prize.

The Ivory Prize Summit is presented in partnership with MOD X, Housing Innovation Alliance, the Arizona Research Center for Housing and Economic Solutions, and the Morrison Institute for Public Policy at Arizona State University.

Attendance and media information

The summit will take place Oct. 14, 2026, at Memorial Union, Arizona State University, 301 E. Orange St., Tempe. Registration, parking, and event information are available at ivoryinnovations.org/ivory-prize-summit.

Reporters interested in attending, covering the summit or requesting interviews should contact Ivory Innovations Director of Marketing Anna Burleson at [email protected].

About Ivory Innovations

Ivory Innovations is an operating foundation and academic center based at the University of Utah David Eccles School of Business. Through programs including Hack-A-House, it supports innovative approaches to addressing housing affordability. For more information visit ivoryinnovations.org.

SOURCE Ivory Innovations

Share this article

VUSSENS Establishes U.S. Headquarters in New Jersey and Launches AI-Powered Global Beauty Analytics Platform

Establishing a Strategic Foothold in North America, the World's Largest Beauty Market, to Accelerate Expansion Across Global Brands, Manufacturers, and Retailers

FORT LEE, N.J. and SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- VUSSENS Inc., a global beauty AI analytics company and a wholly owned subsidiary of NEWEN AI, a specialist in industry-specific AI analytics solutions, has established its North American operations in New Jersey and officially launched VUSSENS, its ontology-based AI beauty analytics platform.

New Jersey, where the North American subsidiary is based, is strategically located adjacent to New York, a major global hub for international business and consumer goods distribution, offering strong infrastructure and accessibility. VUSSENS plans to further strengthen its localization strategy in the North American market by actively leveraging its local partnership network, including connections with New York University (NYU) Stern and the Global AI Frontier Lab based in New York.

The VUSSENS platform, officially unveiled alongside the establishment of the North American subsidiary, is a beauty-specialized, ontology-based AI platform that integrates and analyzes cross-channel data from social media and e-commerce platforms in the U.S. market. Powered by a language model trained on more than 800 billion tokens and a multimodal AI engine capable of simultaneously analyzing video, audio, and subtitles across short-form content platforms such as YouTube and TikTok, VUSSENS enables highly granular persona analysis based on race, age, skin type, and consumer values. Going beyond simple measurements of keyword mentions, the platform structurally maps complex relationships such as trends and sales, ingredients and efficacy, and consumer responses and products, providing actionable market insights for businesses in the local market.

The platform integrates four core solutions, Marketing, Trend, Product, and Category, to support practical business decision-making. The Marketing Solution tracks the entire journey from product seeding and content engagement to reviews and purchase-conversion signals, while the Trend Solution captures diverse consumer responses in real time across ingredients, efficacy, formulations, colors, memes, and other dimensions. In addition, the Product Solution supports customized strategy development through AI-powered SWOT analysis and target-consumer analysis, while the Category Solution provides an overview of market movements and category-level opportunities. The platform also features K-Beauty trend analysis, which is gaining attention as a key benchmark in the global beauty market, further strengthening VUSSENS' competitive edge.

VUSSENS plans to pursue an aggressive sales strategy targeting the entire beauty value chain in North America. Its target customers include beauty brands seeking trend intelligence and marketing performance measurement, OEM and ODM manufacturers looking to optimize new product development and ingredient R&D, major retailers seeking to identify promising brands at an early stage, and agencies requiring sophisticated, data-driven insights for strategic proposals and solutions.

VUSSENS has also outlined a concrete roadmap for business expansion. Starting with its New Jersey subsidiary, the company plans to secure its initial customer base and gradually expand its sales hubs across key regions in the U.S., including the West Coast, South, and Midwest, ultimately building a sales network spanning North America. Building on its success in the North American market, VUSSENS plans to gradually expand its services into other major global beauty markets, including Japan, Europe, Southeast Asia, and the Middle East, with the goal of establishing itself as a global beauty data hub.

*NEWEN AI(KOSDAQ, 463020)

About VUSSENS

VUSSENS is an AI-powered global beauty analytics platform that integrates and analyzes global e-commerce and social media data to identify beauty market trends, consumer demand, and changes across products and categories. By integrating major commerce and social data sources, VUSSENS delivers actionable insights across the entire beauty intelligence ecosystem, from Trends →Categories → Products → Marketing. One of VUSSENS' key strengths lies in its ability to connect data across otherwise fragmented channels, enabling businesses to identify emerging beauty trends and early consumer interest signals, while uncovering high-growth categories and product opportunities.

For more information about VUSSENS, please visit the official website: https://vussens.ai

Product Inquiry[email protected]

SOURCE NEWEN AI

Share this article